|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 8/06/21 Boston Scientific Corp. 10-Q 6/30/21 65:11M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.29M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
12: R1 Cover Document HTML 79K
13: R2 Consolidated Statements of Operations (Unaudited) HTML 109K
14: R3 Consolidated Statements of Comprehensive Income HTML 42K
(Loss)
15: R4 Consolidated Balance Sheets (Unaudited) HTML 113K
16: R5 Consolidated Balance Sheets (Parenthetical) HTML 33K
17: R6 Consolidated Statements of Stockholders' Equity HTML 95K
(Unaudited)
18: R7 Consolidated Statements of Cash Flows (Unaudited) HTML 132K
19: R8 Consolidated Statements of Cash Flows HTML 29K
(Supplemental Disclosure)
20: R9 Basis of Presentation HTML 23K
21: R10 Acquisitions and Strategic Investments HTML 77K
22: R11 Goodwill and Other Intangible Assets HTML 63K
23: R12 Hedging Activities and Fair Value Measurements HTML 255K
24: R13 Contractual Obligations and Commitments HTML 83K
25: R14 Supplemental Balance Sheet Information HTML 110K
26: R15 Income Taxes HTML 29K
27: R16 Commitments and Contingencies HTML 47K
28: R17 Stockholders' Equity HTML 26K
29: R18 Weighted Average Shares Outstanding HTML 41K
30: R19 Segment Reporting HTML 71K
31: R20 Revenue HTML 118K
32: R21 Changes in Other Comprehensive Income HTML 82K
33: R22 New Accounting Pronouncements HTML 26K
34: R23 Basis of Presentation Basis of Presentation HTML 20K
(Policies)
35: R24 Fair Value Measurements Hedging Activities and HTML 24K
Fair Value Measurements (Policies)
36: R25 Commitments and Contingencies Commitments and HTML 20K
Contingencies (Policies)
37: R26 New Accounting Pronouncements (Policies) HTML 31K
38: R27 Acquisitions and Strategic Investments (Tables) HTML 76K
39: R28 Goodwill and Other Intangible Assets Goodwill HTML 59K
(Tables)
40: R29 Hedging Activities and Fair Value Measurements HTML 235K
(Tables)
41: R30 Contractual Obligations and Commitments (Tables) HTML 78K
42: R31 Supplemental Balance Sheet Information (Tables) HTML 119K
43: R32 Income Taxes (Tables) HTML 24K
44: R33 Weighted Average Shares Outstanding (Tables) HTML 40K
45: R34 Segment Reporting (Tables) HTML 65K
46: R35 Revenue (Tables) HTML 110K
47: R36 Changes in Other Comprehensive Income (Tables) HTML 80K
48: R37 Acquisitions (Details) HTML 106K
49: R38 Contingent Consideration (Details) HTML 57K
50: R39 Strategic Investments (Details) HTML 34K
51: R40 Goodwill and Other Intangible Assets (Details) HTML 141K
52: R41 Hedging Activities and Fair Value Measurements HTML 291K
(Details)
53: R42 Contractual Obligations and Commitments (Details) HTML 136K
54: R43 Supplemental Balance Sheet Information (Details) HTML 175K
55: R44 Income Taxes (Details) HTML 28K
56: R45 Commitments and Contingencies (Details) HTML 59K
57: R46 Stockholders' Equity (Details) HTML 57K
58: R47 Weighted Average Shares Outstanding (Details) HTML 41K
59: R48 Segment Reporting (Details) HTML 72K
60: R49 Revenue (Details) HTML 94K
61: R50 Changes in Other Comprehensive Income (Details) HTML 79K
63: XML IDEA XML File -- Filing Summary XML 113K
11: XML XBRL Instance -- bsx-20210630_htm XML 3.55M
62: EXCEL IDEA Workbook of Financial Reports XLSX 112K
7: EX-101.CAL XBRL Calculations -- bsx-20210630_cal XML 213K
8: EX-101.DEF XBRL Definitions -- bsx-20210630_def XML 970K
9: EX-101.LAB XBRL Labels -- bsx-20210630_lab XML 2.00M
10: EX-101.PRE XBRL Presentations -- bsx-20210630_pre XML 1.18M
6: EX-101.SCH XBRL Schema -- bsx-20210630 XSD 170K
64: JSON XBRL Instance as JSON Data -- MetaLinks 429± 632K
65: ZIP XBRL Zipped Folder -- 0000885725-21-000036-xbrl Zip 399K
| Document |
| 1 | I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation; | |||||||
| 2 | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |||||||
| 3 | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |||||||
| 4 | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |||||||
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |||||||
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |||||||
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |||||||
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and | |||||||
| 5 | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): | |||||||
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | |||||||
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. | |||||||
| Date: | August 6, 2021 | /s/ Michael F. Mahoney | ||||||||||||
| Michael F. Mahoney | ||||||||||||||
| Chief Executive Officer | ||||||||||||||
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/6/21 | 4 | ||
| For Period end: | 6/30/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/13/21 Boston Scientific Corp. 8-K:1,2,9 5/10/21 12:1.2M Toppan Merrill/FA |